{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-018705","form_type":"8-K","ticker":"AEON","cik":"0001837607","company_name":"AEON Biopharma, Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.919415+00:00","generated_at":"2026-06-08T05:25:41.249821+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"AEON Biopharma Q3 cash $16.2M; Phase 2 episodic migraine misses primary endpoint","bullets":["Cash, equivalents and investments $16.2M as of Sep 30, 2023; expects to fund operations only into mid-December 2023.","Phase 2 episodic migraine trial missed primary endpoint: mean MMD reduction 4.8 (150U) and 5.0 (195U) vs 4.2 placebo, not statistically significant.","Secondary endpoints achieved statistical significance; company plans to advance to Phase 3 and request end-of-phase 2 meeting with FDA in 1H 2024.","Chronic migraine Phase 2 enrollment on track to complete Q4 2023, topline data expected 2H 2024.","Completed business combination and post-merger funding of ~$50M from new and existing investors."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-018705","json":"https://secwatch.observer/filing/0001558370-23-018705.json","markdown":"https://secwatch.observer/filing/0001558370-23-018705.md","text":"https://secwatch.observer/filing/0001558370-23-018705.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1837607/000155837023018705/0001558370-23-018705-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1837607/000155837023018705/aeon-20231113x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:25:41.249821+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e79e0643bc9bda7116ce79f7523b755d7417ae10","claim":"AEON Biopharma, Inc. reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"AEON Biopharma, Inc. (the \"Company\") announced financial results for the fiscal quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1837607/000155837023018705/0001558370-23-018705-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}